Servier

Aitia expands collaboration with Servier to use causal AI and Gemini Digital Twins for glioma drug discovery, aiming to leverage patient data for novel treatments.

Aitia expands collaboration with Servier to discover and develop new drugs for brain cancer using AI-driven Digital Twins, aiming to leverage Aitia's Gemini Digital Twins and Servier's oncology expertise to find treatments for gliomas.

Fennec Pharmaceuticals appoints Pierre S. Sayad as Chief Medical Officer, Terry Evans as Chief Commercial Officer, and Christiana Cioffi as Chief Strategy Officer to strengthen its executive team and accelerate the commercialization of PEDMARK, the first therapy to reduce ototoxicity risk from cisplatin treatment in pediatric patients.

Alto Neuroscience's Phase 2b trial of ALTO-100 for depression failed to show significant improvement over placebo, raising doubts about its precision medicine approach. Despite this, the company remains confident in its biomarker stratification strategy and is continuing a Phase 2b trial for ALTO-300, expected to report data in 2025.

Early-phase oncology trials now focus on efficacy with novel immunotherapeutic agents like bispecific antibodies and CAR T-cell therapy, necessitating refined trial designs, patient selection strategies, pharmacodynamics markers, and adverse event management. Submissions on exceptional toxicities, progress reviews, and early-stage clinical trials are welcomed.

Pharmas focus on Phase II companies, with 40% of M&A deals completed in under six weeks. Capital markets remain uncertain, leading to more private companies with advanced assets. Deals are more competitive, with mid-caps and European players becoming active acquirers.

Servier partners with Klineo to enhance clinical trial access for patients, initially focusing on oncology trials in France. The collaboration aims to improve information accessibility, particularly for rare cancers, with potential expansion to other countries and studies.

OPM announces poster presentation on OPM-101, a RIPK2 kinase inhibitor, at UEG Week 2024. The presentation by Professor Laurent Peyrin-Biroulet and Bruno Robin will discuss safety, pharmacokinetic, and pharmacodynamic data from Phase 1 in healthy volunteers. The poster, titled 'Unveiling the strong safety profile and high target engagement of OPM-101,' will be presented on October 13, 2024, at 3:30-4:30pm CEST. OPM is a biopharmaceutical company specializing in precision medicine for resistant and metastatic cancers.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.